## Michael Schwarzinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2669338/publications.pdf

Version: 2024-02-01

71 papers

3,732 citations

201674 27 h-index 59 g-index

74 all docs

74 docs citations

74 times ranked 6172 citing authors

#	Article	IF	CITATIONS
1	COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health, The, 2021, 6, e210-e221.	10.0	557
2	Empirical versus Preemptive Antifungal Therapy for Highâ€Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2009, 48, 1042-1051.	5.8	356
3	Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. PLoS ONE, 2010, 5, e10208.	2.5	286
4	Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine, 2012, 40, 104-111.	0.9	260
5	Alcohol use and dementia: a systematic scoping review. Alzheimer's Research and Therapy, 2019, 11, 1.	6.2	244
6	Low Acceptability of A/H1N1 Pandemic Vaccination in French Adult Population: Did Public Health Policy Fuel Public Dissonance?. PLoS ONE, 2010, 5, e10199.	2.5	213
7	Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. Lancet Public Health, The, 2018, 3, e124-e132.	10.0	202
8	Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. British Journal of Haematology, 2001, 115, 630-641.	2.5	139
9	Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut, 2018, 67, 1261-1268.	12.1	104
10	Positive attitudes of French general practitioners towards A/H1N1 influenza-pandemic vaccination: A missed opportunity to increase vaccination uptakes in the general public?. Vaccine, 2010, 28, 2743-2748.	3.8	81
11	Cancer Awareness in Atypical Thrombotic Microangiopathies. Oncologist, 2009, 14, 769-779.	3.7	78
12	Detection and Quantification of Mycoplasma genitalium in Male Patients with Urethritis. Clinical Infectious Diseases, 2003, 37, 602-605.	5.8	66
13	Alcohol use disorders and associated chronic disease – a national retrospective cohort study from France. BMC Public Health, 2018, 18, 43.	2.9	60
14	Simultaneous Bilateral Breast and High-Resolution Axillary MRI of Patients with Breast Cancer:Preliminary Results. American Journal of Roentgenology, 2004, 182, 1059-1067.	2.2	57
15	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Journal of Hepatology, 2014, 61, 7-14.	3.7	57
16	Molecular Diagnosis of Renal-Allograft Rejection: Correlation with Histopathologic Evaluation and Antirejection-Therapy Resistance. Transplantation, 2004, 78, 647-653.	1.0	46
17	Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. PLoS ONE, 2015, 10, e0140930.	2.5	46
18	Evaluation of Coleman Lipostructure for Treatment of Facial Lipoatrophy in Patients With Human Immunodeficiency Virus and Parameters Associated With the Efficiency of This Technique. Archives of Dermatology, 2005, 141, 1220-4.	1.4	44

#	Article	IF	Citations
19	Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. Journal of Clinical Virology, 2005, 33, 60-64.	3.1	42
20	Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant <i>Enterobacteriaceae</i> . Infection Control and Hospital Epidemiology, 2016, 37, 272-280.	1.8	41
21	Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008–2013: A nationwide retrospective cohort study. Journal of Hepatology, 2017, 67, 454-461.	3.7	41
22	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	2.5	41
23	Chronic hepatitis C virus infection: Does it really impact health-related quality of life? A study in rural Egypt. Hepatology, 2004, 40, 1434-1441.	7.3	38
24	Effect of Nucleoside and Nucleotide Analogues on Renal Function in Patients With Chronic Hepatitis B VirusÂMonoinfection. Clinical Gastroenterology and Hepatology, 2015, 13, 1181-1188.e1.	4.4	36
25	Tobacco and COVID-19: a crisis within a crisis?. Canadian Journal of Public Health, 2020, 111, 995-999.	2.3	31
26	Pandemic Influenza (A/H1N1) Vaccine Uptake among French Private General Practitioners: A Cross Sectional Study in 2010. PLoS ONE, 2012, 7, e41837.	2.5	29
27	Correlates of general practitioners' recommendations to patients regarding vaccination for the 2009–2010 pandemic influenza (A/H1N1) in France: Implications for future vaccination campaigns. Vaccine, 2014, 32, 2281-2287.	3.8	29
28	Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine, 2003, 21, 3614-3622.	3.8	28
29	Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study. Journal of Hepatology, 2017, 66, 514-520.	3.7	28
30	Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model. PLoS ONE, 2013, 8, e65776.	2.5	27
31	Addressing COVID-19 vaccine hesitancy: is official communication the key?. Lancet Public Health, The, 2021, 6, e353-e354.	10.0	24
32	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. Journal of Hepatology, 2022, 76, 265-274.	3.7	24
33	Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation1. Transplantation, 2004, 77, 854-858.	1.0	23
34	Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness analysis from the perspective of the French national health insurance system. Health Policy, 2008, 88, 186-199.	3.0	23
35	Risk factors for bronchiolitis hospitalization in infants: AÂFrench nationwide retrospective cohort study over four consecutive seasons (2009-2013). PLoS ONE, 2020, 15, e0229766.	2.5	23
36	Factors Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the Pandemic A/H1N1 Virus in the French General Population. PLoS ONE, 2013, 8, e60127.	2.5	21

#	Article	IF	CITATIONS
37	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS ONE, 2016, 11, e0157191.	2.5	19
38	Forecasting the prevalence of dementia. Lancet Public Health, The, 2022, 7, e94-e95.	10.0	19
39	Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage. PLoS ONE, 2019, 14, e0215596.	2.5	17
40	Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistance and Infection Control, 2013, 2, 30.	4.1	16
41	Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. BMC Public Health, 2012, 12, 417.	2.9	15
42	Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries. Vaccine, 2022, 40, 178-182.	3.8	15
43	Antibiotic Treatment for Influenza does not Affect Resolution of Illness, Secondary Visits or Lost Workdays. European Journal of Epidemiology, 2003, 19, 703-705.	5.7	14
44	49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188). Journal of Hepatology, 2013, 58, S21-S22.	3.7	14
45	The breast cancer related burden of morbidity and mortality in six European countries: The European Disability Weights project. European Journal of Public Health, 2004, 14, 141-146.	0.3	13
46	HIV-serodiscordant couples desiring a child: †treatment as prevention,†preexposure prophylaxis, or medically assisted procreation?. American Journal of Obstetrics and Gynecology, 2015, 213, 341.e1-341.e12.	1.3	13
47	Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France. Vaccine, 2018, 36, 1285-1296.	3.8	13
48	Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. Journal of Epidemiology and Community Health, 2015, 69, 272-277.	3.7	11
49	Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults. Pharmacoeconomics, 2003, 21, 215-224.	3.3	10
50	Lack of multiplicative transitivity in person trade-off responses. Health Economics (United Kingdom), 2004, 13, 171-181.	1.7	10
51	"lf you have the flu symptoms, your asymptomatic spouse may better answer the willingness-to-pay questionâ€, Journal of Health Economics, 2009, 28, 873-884.	2.7	10
52	Effectiveness and cost of quick diagnostic tests to determine tetanus immunity in patients with a wound in french emergency departments. BMC Infectious Diseases, 2014, 14, 603.	2.9	8
53	<p>Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France</p> . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 441-451.	1.9	7
54	Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infectionsâ€"The Fluco French cohort. Journal of Clinical Virology, 2013, 58, 114-119.	3.1	6

#	Article	IF	Citations
55	Prolonged Hospital Stay, an Adverse Effect of Strict National Policy for Controlling the Spread of Highly Resistant Microorganisms. Infection Control and Hospital Epidemiology, 2014, 35, 1427-1429.	1.8	6
56	Generic antiretroviral drugs and HIV care: An economic review. Médecine Et Maladies Infectieuses, 2016, 46, 67-71.	5.0	6
57	Economic evaluations of neuraminidase inhibitors to control influenza. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 147-158.	1.4	5
58	Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health, 2010, 10, 773.	2.9	5
59	O1â€08â€04: The Neglected Role of Alcohol use Disorders in Earlyâ€Onset Dementia: a Nationwide Study From France. Alzheimer's and Dementia, 2016, 12, P194.	0.8	4
60	Estimating health state utility from activities of daily living in the French National Hospital Discharge Database: a feasibility study with head and neck cancer. Health and Quality of Life Outcomes, 2019, 17, 129.	2.4	4
61	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population. Vaccines, 2021, 9, 1364.	4.4	4
62	Reply to Marr et al. Clinical Infectious Diseases, 2009, 49, 1139-1140.	5.8	3
63	Risk Factors and Scoring System for Predicting Bacterial Resistance to Cefepime as Used Empirically in Haematology Wards. BioMed Research International, 2015, 2015, 1-8.	1.9	3
64	"Who killed JR― Chronic hepatitis C or alcohol use disorders?. Journal of Hepatology, 2018, 68, 1098-1099.	3.7	3
65	Factors associated with under-reporting of head and neck squamous cell carcinoma in cause-of-death records: A comparative study of two national databases in France from 2008 to 2012. PLoS ONE, 2021, 16, e0246252.	2.5	3
66	Prolonged Hospital Stay, an Adverse Effect of Strict National Policy for Controlling the Spread of Highly Resistant Microorganisms. Infection Control and Hospital Epidemiology, 2014, 35, 1427-1429.	1.8	2
67	Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database†Journal of Hepatology, 2022, 76, 744-747.	3.7	2
68	Reply to Stefani et al. Clinical Infectious Diseases, 2010, 50, 1202-1203.	5.8	0
69	Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012. Therapie, 2013, 68, 259-263.	1.0	0
70	Authors' reply. Lancet Public Health, The, 2018, 3, e217.	10.0	0
71	Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients― Journal of Hepatology, 2021, , .	3.7	0